Please ensure Javascript is enabled for purposes of website accessibility

Why TherapeuticsMD Inc. Is Falling Today

By Brian Feroldi - Updated Apr 10, 2017 at 11:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares tanked after the company announced that it received some bad news from the FDA related to TX-004HR.

What happened

Investors in TherapeuticsMD (TXMD -3.60%), a clinical-stage biotech company focused on women's health, are having a rough start to the week. The company's stock is down 16% as of 11:25 a.m. EDT in response to the news that it has received a troublesome letter from the Food and Drug Administration. 

A physician looking concerned

Image source: Getty Images.

So what

TherapeuticsMD informed investors that it has received a letter from the FDA related to its pending application of Yuvvexy, or TX-004HR. The drug was submitted in 2016 as a hopeful treatment of vaginal pain during sexual intercourse caused by menopause. 

The letter itself was light on details but it did state that the agency has "identified deficiencies" in the company's application that will prevent it from holding discussing on labeling and postmarketing commitments at this time.

Unfortunately, that's all the information investors have at the moment since the letter did not specify which deficiencies were identified or provide an updated timeline. Predictably, management stated that it intends to work closely with the FDA to resolve these problems as quickly as possible.

Wall Street is reacting harshly to this unexpected turn of events, so shares are tumbling today.

Now what

Management was quick to point out that this letter does not contain a final go/no-go decision on Yuvvexy. In addition, the company was not provided with an updated timeline, so they do not know if the former PDUFA date of May 7, 2017, is still valid or not. 

With little information to go on, it is hard to know what investors should do next. Thus far, the clinical data on Yuvvexy has looked solid, which is why some market watchers believe that the drug will produce more than $1 billion in peak sales. However, regulatory approval and commercial success are never guaranteed, so the risks here are still quite high.

Given the lack of details, I'd suggest that potential investors remain on the sidelines until we have more information about what is causing the holdup.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TherapeuticsMD, Inc. Stock Quote
TherapeuticsMD, Inc.
TXMD
$9.64 (-3.60%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.